JP2023512276A5 - - Google Patents
Info
- Publication number
- JP2023512276A5 JP2023512276A5 JP2022546505A JP2022546505A JP2023512276A5 JP 2023512276 A5 JP2023512276 A5 JP 2023512276A5 JP 2022546505 A JP2022546505 A JP 2022546505A JP 2022546505 A JP2022546505 A JP 2022546505A JP 2023512276 A5 JP2023512276 A5 JP 2023512276A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- product according
- cancer
- inhibitor
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062967875P | 2020-01-30 | 2020-01-30 | |
| EP20382054.3 | 2020-01-30 | ||
| EP20382054 | 2020-01-30 | ||
| US62/967,875 | 2020-01-30 | ||
| PCT/IB2021/050747 WO2021152548A1 (en) | 2020-01-30 | 2021-01-29 | Combination therapy for treatment of cancer and cancer metastasis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023512276A JP2023512276A (ja) | 2023-03-24 |
| JP2023512276A5 true JP2023512276A5 (cg-RX-API-DMAC7.html) | 2024-02-06 |
Family
ID=74347467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022546505A Pending JP2023512276A (ja) | 2020-01-30 | 2021-01-29 | 癌及び癌転移の治療のための併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230086099A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4097130A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023512276A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220133996A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115397859A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021213969A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022014962A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3168923A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL295093A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022009270A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021152548A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021176424A1 (en) | 2020-03-06 | 2021-09-10 | Ona Therapeutics, S.L. | Anti-cd36 antibodies and their use to treat cancer |
| CA3226281A1 (en) * | 2021-07-30 | 2023-02-02 | ONA Therapeutics S.L. | Anti-cd36 antibodies and their use to treat cancer |
| WO2023172863A1 (en) * | 2022-03-07 | 2023-09-14 | Elixiron Immunotherapeutics (hong Kong) Limited | Anti-cd36 antibodies and uses thereof |
| CN117462687A (zh) * | 2022-07-20 | 2024-01-30 | 清华大学 | 一种用于制备预防或治疗骨转移癌药物的组合物及其应用 |
| CN118697878B (zh) * | 2024-05-28 | 2025-02-11 | 广东省人民医院 | Cd36作为抑制肺癌脑膜转移的分子标志物和治疗靶点的应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| MXPA02001878A (es) | 1999-08-23 | 2003-08-20 | Dana Farber Cancer Inst Inc | Moleculas b7-4 novedosas y usos de las mismas. |
| ES2539411T3 (es) | 1999-08-23 | 2015-06-30 | Dana-Farber Cancer Institute, Inc. | PD-1, receptor para la B7-4 y su utilización |
| CA3016482A1 (en) | 1999-11-30 | 2001-06-07 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
| WO2003032813A2 (en) | 2001-10-18 | 2003-04-24 | Genentech Inc. | Methods for the treatment of carcinoma |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EA201500417A1 (ru) | 2008-08-25 | 2015-11-30 | Эмплиммьюн, Инк. | Композиции антагонистов pd-1 и способы применения |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| US9175082B2 (en) | 2012-05-31 | 2015-11-03 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| RS61400B1 (sr) | 2013-05-02 | 2021-02-26 | Anaptysbio Inc | Antitela usmerena protiv programirane smrti-1 (pd-1) |
| CA3175360C (en) | 2013-05-31 | 2024-05-28 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| CA2971734C (en) | 2014-12-22 | 2025-11-18 | Pd-1 Acquisition Group, Llc | Anti-pd-1 antibodies |
| MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| HRP20201334T1 (hr) | 2015-04-17 | 2020-11-27 | Bristol-Myers Squibb Company | Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba |
| WO2016197367A1 (en) | 2015-06-11 | 2016-12-15 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| PE20231958A1 (es) | 2015-07-30 | 2023-12-06 | Macrogenics Inc | Moleculas de union a pd-1 y metodos de uso de las mismas |
| WO2017020291A1 (en) | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| WO2017024515A1 (en) | 2015-08-11 | 2017-02-16 | Wuxi Biologics (Cayman) Inc. | Novel anti-pd-1 antibodies |
| MX392711B (es) | 2015-08-11 | 2025-03-24 | Wuxi Biologics Ireland Ltd | Anticuerpos anti-pd-1 novedosos. |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| JP6869987B2 (ja) | 2015-09-01 | 2021-05-12 | アジェナス インコーポレイテッド | 抗pd−1抗体及びその使用方法 |
| EP3650468A1 (en) | 2015-09-29 | 2020-05-13 | Fundació Institut de Recerca Biomèdica (IRB Barcelona) | Targeting metastasis stem cells through a fatty acid receptor (cd36) |
| CN108367069B (zh) | 2015-12-14 | 2022-08-23 | 宏观基因有限公司 | 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法 |
| JP7082051B2 (ja) | 2016-01-11 | 2022-06-07 | アルモ・バイオサイエンシーズ・インコーポレイテッド | 抗原特異的cd8+t細胞の産生におけるインターロイキン-10及びその使用方法 |
| EP3402255B1 (en) | 2016-02-02 | 2021-03-31 | Huawei Technologies Co., Ltd. | Emission power verification method, user equipment, and base station |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| EP3618829B1 (en) * | 2017-05-05 | 2023-06-07 | Arcus Biosciences, Inc. | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders |
| CN111315398A (zh) * | 2017-11-10 | 2020-06-19 | 阿尔莫生物科技股份有限公司 | 白介素-10与免疫检查点途径抑制剂的组合的组合物和使用方法 |
| GB201802307D0 (en) * | 2018-02-13 | 2018-03-28 | Vib Vzw | CD36 antagonists for use in melanoma treatment |
| WO2019173682A1 (en) * | 2018-03-09 | 2019-09-12 | Arcus Biosciences, Inc. | Parenterally administered immune enhancing drugs |
| CA3109563A1 (en) * | 2018-09-14 | 2020-03-19 | Universite De Lausanne | Methods for modulating regulatory t cells and inhibiting tumor growth |
-
2021
- 2021-01-29 AU AU2021213969A patent/AU2021213969A1/en not_active Abandoned
- 2021-01-29 CA CA3168923A patent/CA3168923A1/en active Pending
- 2021-01-29 CN CN202180026925.1A patent/CN115397859A/zh active Pending
- 2021-01-29 JP JP2022546505A patent/JP2023512276A/ja active Pending
- 2021-01-29 KR KR1020227030035A patent/KR20220133996A/ko not_active Ceased
- 2021-01-29 EP EP21702319.1A patent/EP4097130A1/en not_active Withdrawn
- 2021-01-29 MX MX2022009270A patent/MX2022009270A/es unknown
- 2021-01-29 WO PCT/IB2021/050747 patent/WO2021152548A1/en not_active Ceased
- 2021-01-29 US US17/795,814 patent/US20230086099A1/en not_active Abandoned
- 2021-01-29 BR BR112022014962A patent/BR112022014962A2/pt not_active IP Right Cessation
- 2021-01-29 IL IL295093A patent/IL295093A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Türeci et al. | A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study | |
| Farley et al. | Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study | |
| Ferté et al. | IGF-1R targeting increases the antitumor effects of DNA-damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy | |
| Tao et al. | Targeting of DDR1 with antibody‐drug conjugates has antitumor effects in a mouse model of colon carcinoma | |
| JP2021532143A5 (cg-RX-API-DMAC7.html) | ||
| Caffo et al. | Innovative therapeutic strategies in the treatment of brain metastases | |
| RU2010142390A (ru) | Комбинации конъюгата анти-her2-антитело-лекарственное средство и химиотерапевтических средств и способы применения | |
| HRP20220399T1 (hr) | Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost | |
| JPWO2022270524A5 (cg-RX-API-DMAC7.html) | ||
| JP2021510697A5 (cg-RX-API-DMAC7.html) | ||
| Tyczyńska et al. | Treatment strategies of gastric cancer—Molecular targets for anti-angiogenic therapy: A state-of-the-art review | |
| JP2024071393A5 (cg-RX-API-DMAC7.html) | ||
| Abushukair et al. | Primary and secondary immune checkpoint inhibitors resistance in colorectal cancer: Key mechanisms and ways to overcome resistance | |
| Yamazaki et al. | Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab | |
| Li et al. | Chidamide and oxaliplatin synergistically inhibit colorectal cancer growth by regulating the RPS27A-MDM2-P53 axis | |
| US20210023211A1 (en) | Combination of anti-fgfr4-antibody and bile acid sequestrant | |
| Chiu et al. | Targeting AXL inhibits the growth and metastasis of prostate cancer in bone | |
| Ahmed et al. | Exploring the tumor microenvironment in solid cancer: From biology to therapy | |
| Reibenwein et al. | Targeting signaling pathways in ovarian cancer | |
| Wu et al. | Novel perspectives on MSLN-targeted cancer therapy: from molecular mechanisms to clinical translation | |
| JP2017535548A5 (cg-RX-API-DMAC7.html) | ||
| JP2026015500A5 (cg-RX-API-DMAC7.html) | ||
| JP2022537453A5 (cg-RX-API-DMAC7.html) | ||
| RU2019107115A (ru) | Комбинации для лечения рака, включающие abx196 | |
| JP2024536719A5 (cg-RX-API-DMAC7.html) |